Novita Pharmaceuticals, Inc.

Quick facts

Phase 2 pipeline

• Anti-PD-1 Therapy · Oncology
  Inhibits PD-1 receptor

Phase 1 pipeline

• NP-G2-044 Combination therapy
• NP-G2-044 Monotherapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Novita Pharmaceuticals, Inc. portfolio CI brief
• Novita Pharmaceuticals, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies